Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Sirukumab in the Treatment of Patients With Giant Cell Arteritis
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Sirukumab (Primary) ; Prednisone
- Indications Giant cell arteritis
- Focus Registrational; Therapeutic Use
- Acronyms SIRRESTA
- Sponsors GlaxoSmithKline; GSK
- 01 May 2022 According to a Form 6-K, 2022, company SEC filing, GlaxoSmithKline has changed its name to GSK.
- 03 Apr 2022 This trial has been completed in Italy (End Date: 20 Mar 2018), according to European Clinical Trials Database record.
- 15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism